There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Reviva Pharmaceuticals Holdings (RVPH – Research Report), Roivant Sciences (ROIV – Research Report) and Poseida Therapeutics (PSTX – Research Report) with bullish sentiments.
Reviva Pharmaceuticals Holdings (RVPH)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Reviva Pharmaceuticals Holdings today and set a price target of $20.00. The company’s shares closed last Friday at $3.02, close to its 52-week low of $2.67.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of
Reviva Pharmaceuticals Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.
See the top stocks recommended by analysts >>
Roivant Sciences (ROIV)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Roivant Sciences, with a price target of $18.00. The company’s shares closed last Friday at $10.46.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
Currently, the analyst consensus on Roivant Sciences is a Strong Buy with an average price target of $17.00.
Poseida Therapeutics (PSTX)
In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Poseida Therapeutics, with a price target of $20.00. The company’s shares closed last Friday at $2.02.
According to TipRanks.com, CFA is a 3-star analyst with an average return of
Poseida Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.00, implying a 600.0% upside from current levels. In a report issued on April 8, William Blair also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RVPH:
- Reviva Pharmaceuticals’ Financial Turmoil: The High Cost of Restating Finances and its Impact on Stability
- Reviva Pharmaceuticals Advances Schizophrenia Treatment Trials
- Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
- Reviva Pharmaceuticals announces FDA alignment on brilaroxazine trial
- Reviva Pharmaceuticals: Insights from Latest SEC Report
